Aurinia Pharmaceuticals Inc. - Special Call Transcript
Greetings. And welcome to the Aurinia Pharmaceuticals AURORA clinical trials results conference. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mr. Glenn Schulman, Head of Investor Relations. Thank you. You may begin.
Thanks, Dana, and good morning, everyone. Thanks for joining us as we take the time to review the top line efficacy and safety results from the AURORA Phase III clinical trial with voclosporin. Joining me on the call this morning from the Aurinia team are: Mr. Peter Greenleaf, President and CEO; and Dr. Neil Solomons, Chief Medical Officer. Last night, we issued a press release detailing the results, which are available on our website at www.auriniapharma.com, along with a 6-K that's being filed with the SEC.
I'd like to remind you that today's call is also being webcast live on Aurinia's Investor
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |